Can-Fite BioPharma Ltd.CANFNYSE

|||

Overview News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 75% recommend buying.

Consensus Rating

Buy

4 analysts·Low coverage

75%

Rating Distribution

Strong Buy

00%

Buy

375%

Hold

125%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 3195% higher.

Bear Case

$4.50

+1945%

Consensus

$7.25

+3195%

Bull Case

$10.00

+4445%

Price Range4 analysts

Low

Consensus

High

$4.50

$10.00

Current Target

Current Price

$0.22

Upside to Target

$7.03

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-0.02(1 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+315.86%

EPS—

FY2028

Rev+96.72%

EPS+97.50%

FY2029

Rev+55.14%

EPS+45.57%

Earnings Surprises

Beat rate:42%(5/12 quarters)

Avg surprise:-149.6%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Apr 15, 2025Industrial Alliance Securities

Can-Fite price target lowered to $4.50 from $12 at Alliance Global Partners

Target:$4.50

+186.6%from $1.57

Jul 17, 2024EF Hutton

Can-Fite BioPharma initiated with a Buy at EF Hutton

Target:$10.00

+173.2%from $3.66

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance